Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 3545.

https://doi.org/10.1182/blood-2019-122685

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Jo Howard, Claire Jane Hemmaway, Paul Telfer, D. Mark Layton, John Porter, Moji Awogbade, Timothy Mant, Daniel D. Gretler, Kobina Dufu, Athiwat Hutchaleelaha, Mira Patel, Vincent Siu, Sandra Dixon, Noel Landsman, Margaret Tonda, Joshua Lehrer-Graiwer

Blood (2019) 133 (17): 1865–1875.

https://doi.org/10.1182/blood-2018-08-868893

Published: 2019

Journal Articles

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 163.

https://doi.org/10.1182/blood-2018-163

Published: 2018

Journal Articles

Pregnancy Outcomes in Patients with Sickle Cell Syndromes Managed Antenatally with Exchange Transfusions: A Single Centre Analysis

Evangelia Vlachodimtropoulou Koumoutsea, MBBS, Hutachok Nuntouchaporn, BSc, Perla Eleftheriou, FRCPath, MRCP, Patrick O'Brien, John Porter, MA MDFRCP FRCPath

Blood (2018) 132 (Supplement 1): 3666.

https://doi.org/10.1182/blood-2018-99-113619

Published: 2018

Journal Articles

Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults

John Porter, MA MD FRCP FRCPath, Kris Kowdley, MD, Ali Taher, MD PhD, Jeffrey Vacirca, MD, Zancong Shen, PhD, Steve Chen, MD, Lakhmir Chawla, MD, George Tidmarsh, MD PhD

Blood (2018) 132 (Supplement 1): 2336.

https://doi.org/10.1182/blood-2018-99-110885

Published: 2018

Journal Articles

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Simon Cheesman, Raakhee Shah, MPharm, Sara Trompeter, MD, Perla Eleftheriou, FRCPath, MRCP, Bernadette Hylton, RN, Maciej W Garbowski, MDPhD, John Porter, MA MDFRCP FRCPath

Blood (2018) 132 (Supplement 1): 1062.

https://doi.org/10.1182/blood-2018-99-119030

Published: 2018

Journal Articles

Lentiglobin Gene Therapy for Patients with Transfusion-Dependent β-Thalassemia (TDT): Results from the Phase 3 Northstar-2 and Northstar-3 Studies

Franco Locatelli, Mark C. Walters, MD, Janet L. Kwiatkowski, MD, John Porter, MA MDFRCP FRCPath, Martin G. Sauer, MD, Isabelle Thuret, MD, Suradej Hongeng, MD, Andreas E. Kulozik, MD PhD, Ashutosh Lal, MD, Adrian J. Thrasher, MD PhD FMedSci, Evangelia Yannaki, MD, Heidi Elliot, Ge Tao, PhD, Mohammed Asmal, MD PhD, Alexis A. Thompson, MD MPH

Blood (2018) 132 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2018-99-112667

Published: 2018

Journal Articles

Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

Laura Chebet Kirui, MRCP, FRCPath, Marie Scully, MD MRCP, FRCPath, Norma Mcqueen, Bsc, John Porter, MA MDFRCP FRCPath, Perla Eleftheriou, FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 4922.

https://doi.org/10.1182/blood-2018-99-118396

Published: 2018

Journal Articles

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Blood (2018) 132 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2018-99-111770

Published: 2018

Journal Articles

Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator

Evangelia Vlachodimitropoulou, Yu-Lin Chen, Maciej Garbowski, Pimpisid Koonyosying, Bethan Psaila, Martha Sola-Visner, Nichola Cooper, Robert Hider, John Porter

Blood (2017) 130 (17): 1923–1933.

https://doi.org/10.1182/blood-2016-10-740241

Published: 2017

Includes: Supplemental data

Journal Articles

A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia

Daniel A. Lichtenstein, Andrew W. Crispin, Anoop K. Sendamarai, Dean R. Campagna, Klaus Schmitz-Abe, Cristovao M. Sousa, Martin D. Kafina, Paul J. Schmidt, Charlotte M. Niemeyer, John Porter, Alison May, Mrinal M. Patnaik, Matthew M. Heeney, Alec Kimmelman, Sylvia S. Bottomley, Barry H. Paw, Kyriacos Markianos, Mark D. Fleming

Blood (2016) 128 (15): 1913–1917.

https://doi.org/10.1182/blood-2016-05-719062

Published: 2016

Includes: Supplemental data

Journal Articles

A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results

Maria-Domenica Cappellini, MD, John Porter, MD, Raffaella Origa, MD, Gian Luca Forni, MD, Adberrahmane Laadem, MD, Frédéric Galacteros, MD PhD, Dimana Miteva, PhD, Victoria Sung, PhD, Rajesh Chopra, MD, Jean-Benoît Arlet, MD, PhD, Jean-Antoine Ribeil, MD, PhD, Kenneth Klesczewski, PhD, Kenneth Attie, MD, Maciej Garbowski, MD, Olivier Hermine, MD, PhD

Blood (2013) 122 (21): 3448.

https://doi.org/10.1182/blood.V122.21.3448.3448

Published: 2013

Journal Articles

Psychological Factors Associated With Episodic Oral Chelation Adherence In Thalassaemia

Vosper Jane, D Clin Psy, Michael Evangeli, Clin Psy D, John Porter, MD, Farrukh Shah, MD

Blood (2013) 122 (21): 4706.

https://doi.org/10.1182/blood.V122.21.4706.4706

Published: 2013

Journal Articles

Assessment Of Non-Transfusional Iron Accumulation In Asian Patients With Hemoglobin E β Thalassemia

Tim G St Pierre, PhD, John Porter, MD, Angela Allen, PhD, Ashok Perera, MD, Dayananda Bandara, MD, A.B. Karunawathi, Anuja Premawardhena, MD, David J Weatherall, FRS, Nancy F Olivieri, MD

Blood (2013) 122 (21): 2262.

https://doi.org/10.1182/blood.V122.21.2262.2262

Published: 2013

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

Journal Articles

Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study)

John Porter, MD, Patrick B Walter, PhD, Lynne D Neumayr, MD, Patricia Evans, PhD, Marcela G Weyhmiller, PhD, Paul Harmatz, MD, John C. Wood, MD, PhD, Jeffery L Miller, MD, Guenter Weiss, MD, Quing Yuan, PhD, Zhiyue J Wang, PhD, Regine Grosse, MD, Bjoern P Schoennagel, MD, Joerg Meerpohl, MD, Roland Fischer, PhD, Peter Nielsen, MD, Markus Seifert, BSc, Elliott Vichinsky, MD

Blood (2013) 122 (21): 1014.

https://doi.org/10.1182/blood.V122.21.1014.1014

Published: 2013

Journal Articles

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Ali T. Taher, John Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini

Blood (2012) 120 (5): 970–977.

https://doi.org/10.1182/blood-2012-02-412692

Published: 2012

Includes: Supplemental data

Journal Articles

The Effects of 24 Hour Continuous Deferoxamine Intensification on Serum Creatinine.

Dima El-Sharkawi, Bernard Davis, John Porter

Blood (2008) 112 (11): 1851.

https://doi.org/10.1182/blood.V112.11.1851.1851

Published: 2008

Journal Articles

Evaluation of Deferasirox (Exjade®, ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) ≤1000 ng/mL in Long-Term Studies.

Maria Domenica Cappellini, Elliott Vichinsky, John M. Ford, Bertrand Rabault, John Porter

Blood (2007) 110 (11): 3795.

https://doi.org/10.1182/blood.V110.11.3795.3795

Published: 2007

NARROW

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Pregnancy Outcomes in Patients with Sickle Cell Syndromes Managed Antenatally with Exchange Transfusions: A Single Centre Analysis

Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Lentiglobin Gene Therapy for Patients with Transfusion-Dependent β-Thalassemia (TDT): Results from the Phase 3 Northstar-2 and Northstar-3 Studies

Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator

A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia

A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results

Psychological Factors Associated With Episodic Oral Chelation Adherence In Thalassaemia

Assessment Of Non-Transfusional Iron Accumulation In Asian Patients With Hemoglobin E β Thalassemia

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study)

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

The Effects of 24 Hour Continuous Deferoxamine Intensification on Serum Creatinine.

Evaluation of Deferasirox (Exjade®, ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) ≤1000 ng/mL in Long-Term Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only